Adc Therapeutics SA (NYSE:ADCT) has a beta value of 1.54 and has seen 1.47 million shares traded in the last trading session. The company, currently valued at $174.43M, closed the last trade at $1.89 per share which meant it lost -$0.09 on the day or -4.55% during that session. The ADCT stock price is -219.58% off its 52-week high price of $6.04 and 46.56% above the 52-week low of $1.01. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.5 million shares traded. The 3-month trading volume is 702.05K shares.
The consensus among analysts is that Adc Therapeutics SA (ADCT) is Buy stock at the moment, with a recommendation rating of 1.29. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 7 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adc Therapeutics SA (NYSE:ADCT) trade information
Sporting -4.55% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ADCT stock price touched $1.89 or saw a rise of 45.85%. Year-to-date, Adc Therapeutics SA shares have moved 13.86%, while the 5-day performance has seen it change -39.62%. Over the past 30 days, the shares of Adc Therapeutics SA (NYSE:ADCT) have changed -32.98%. Short interest in the company has seen 3.01 million shares shorted with days to cover at 6.98.
Wall Street analysts have a consensus price target for the stock at $8, which means that the shares’ value could jump 76.38% from current levels. The projected low price target is $7.0 while the price target rests at a high of $13.0. In that case, then, we find that the current price level is -587.83% off the targeted high while a plunge would see the stock gain -270.37% from current levels.
Adc Therapeutics SA (ADCT) estimates and forecasts
Figures show that Adc Therapeutics SA shares have outperformed across the wider relevant industry. The company’s shares have lost -42.73% over the past 6 months, with this year growth rate of 42.52%, compared to 16.90% for the industry. Revenue growth from the last financial year stood is estimated to be 4.55%.
7 analysts offering their estimates for the company have set an average revenue estimate of 18.85M for the current quarter. 2 have an estimated revenue figure of 19.6M for the next ending quarter. Year-ago sales stood 16.79M and 18.05M respectively for this quarter and the next, and analysts expect sales will grow by 12.27% for the current quarter and 4.55% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -10.46% over the past 5 years.
ADCT Dividends
Adc Therapeutics SA is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Adc Therapeutics SA (NYSE:ADCT)’s Major holders
Insiders own 20.64% of the company shares, while shares held by institutions stand at 63.12% with a share float percentage of 79.54%. Investors are also buoyed by the number of investors in a company, with Adc Therapeutics SA having a total of 105.0 institutions that hold shares in the company. The top two institutional holders are REDMILE GROUP, LLC with over 15.27 million shares worth more than $48.25 million. As of 2024-06-30, REDMILE GROUP, LLC held 18.4964% of shares outstanding.
The other major institutional holder is PROSIGHT MANAGEMENT, LP, with the holding of over 9.57 million shares as of 2024-06-30. The firm’s total holdings are worth over $30.24 million and represent 11.5926% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Russell 2000 ETF and Fidelity Small Cap Index Fund . As of Sep 30, 2024 , the former fund manager holds about 2.09% shares in the company for having 2.02 shares of worth $3.82 million while later fund manager owns 715.85 shares of worth $1.35 million as of Aug 31, 2024 , which makes it owner of about 0.74% of company’s outstanding stock.
